

AACR Special Conference on

Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry

in collaboration with AACR Chemistry in Cancer Research Working Group

December 9-11 | Toronto, ON, Canada

AACR American Association for Cancer Research

2404033E

Current as of November 12, 2024

Poster Session A (To be presented on December 10 from 6:30-8:00 p.m. ET)

A001 **Navigating the Future of Therapeutic Development: Innovations in Safety and Efficacy through Advanced Research Methodologies and Nanotechnology**. Peter David. Eloi Holding, Inc., Middletown, DE, United States.

A002 **Computational Identification for Missense Mutations of Bladder Cancer Candidate Genes Using TCGA Datasets**. Kai He. Greenhills School, Ann Arbor, MI, United States.

A003 **In vitro anticancer activities of some organoplatinum(IV) derivatives**. William Howard. University of Alaska Fairbanks, Fairbanks, AK, United States.

A004 **Broad and synergistic anti-tumor effects of small-molecule inhibitors of hypoxia inducible factors when paired with immune checkpoint blockade**. Shaima Salman. Johns Hopkins University, Baltimore, MD, United States.

A005 / PR001 **Discovery of Etrumadenant, a first-in-class dual A2a and A2b adenosine receptor antagonist for cancer immunotherapy**. Ehesan Sharif. Arcus Biosciences, Hayward, CA, United States.

A006 / PR002 **EP300 loss of function is a pan-cancer sensitizer to BET inhibition**. Tomas Babak. Leapfrog Bio, San Mateo, CA, United States.

A007 **Anti-cancer activity of (Z)-endoxifen-related compounds in ERα+ breast cancer**. Natalie Farris. Atossa Therapeutics Inc, Seattle, WA, United States.

A008 **Evaluation of natural and synthetic compounds on epithelial to mesenchymal transition in triple negative breast cancer**. Asef Faruk. Duquesne University, Pittsburgh, PA, United States.

A009 **Genetic disruption of CAPNS1 impedes triple-negative breast cancer metastasis: A case for selective calpain-1/2 inhibitors**. Danielle Harper. Queen's University, Kingston, ON, Canada.

A010 /PR003 **Structure-guided design and optimization of small molecule CD73 inhibitors with excellent drug-like properties: discovery of quemliclustat**. Jenna Jeffrey. Arcus Biosciences, Hayward, CA, United States.

A011 **Discovery and characterization of the first highly potent and selective AXL receptor tyrosine kinase inhibitor AB801**. Manjunath Lamani. Arcus Biosciences, Hayward, CA, United States.

A012 **Discovery and Characterization of Casdatifan (AB521), a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2α Inhibitor**. Kenneth Lawson. Arcus Biosciences, Inc, Hayward, CA, United States.



AACR Special Conference on
Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry
in collaboration with AACR Chemistry in Cancer Research Working Group
December 9-11 | Toronto, ON, Canada

AACR American Association for Cancer Research

2404033E

A013 **Prioritization of Eleven-Nineteen-Leukemia (ENL) Inhibitors as Orally Available Drug Candidates for Acute Myeloid Leukemia**. Wenshe Liu. Texas A&M University, College Station, TX, United States.

A014 **OICR41103: a chemical probe for investigating DCAF1 function and therapeutic potential**. Mahmoud Noureldin. Ontario Institute for Cancer Research, Toronto, ON, Canada.

A015 **Design and deciphering of precision peptide inhibitors for cancer stemness using generative deep learning and molecular dynamics simulations**. Gurudeeban Selvaraj. Concordia University, Montreal, QC, Canada.

A016 **Targeting calpain-1 and calpain-2 for prevention of breast cancer metastasis: In vivo insights and drug discovery approaches**. Ivan Shapovalov. Queen's University, Kingston, ON, Canada.

A017 **The FES tyrosine kinase as an emerging target for cancer immunotherapy**. Julian Simonetti. Queen's University, Kingston, ON, Canada.

A018 **Somatic mutations in the PIK3CA gene and its prognostic implications among Ethiopian Breast cancer patients**. Zelalem Desalegn Woldesonbet. Addis Ababa University, Addis AbabaEthiopia.

A019 **Discovery of a potent and brain-penetrable tubulin inhibitor SB-216 that shows efficacy in primary tumor growth and brain metastasis**. Wei Li. University of Tennessee Health Science Center, Memphis, TN, United States.

A020 **Liposomal topotecan with low-intensity focused ultrasound utilization to improve drug penetration with brain parenchyma in pediatric brain tumors.** Avani Mangoli. Duke University, Durham, NC, United States.

A021 / PR004 **Brain penetrant allosteric EGFR inhibitors for NSCLC**. David Scott. Dana-Farber Cancer Institute, Boston, MA, United States.

A022 **Discovery of conformationally constrained ALK2 inhibitors for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG)**. David Smil. Ontario Institute for Cancer Research, Toronto, ON, Canada.

A023 / PR005 **Helping academic investigators develop small molecules for the clinic: The NCI Developmental Therapeutics Program and Stepping-Stones**. Sharad Verma. National Cancer Institute, Rockville, MD, United States.